GlassScriptPhysician profile
John A Dacosta
NPI 1932133642
$14,266.75
in general payments reported to CMS, 2019-2025
29 companies · $2,191 in 2025
The $2,191 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,709 · 2020: $1,503 · 2021: $1,184 · 2022: $2,350 · 2023: $2,830 · 2024: $2,501 · 2025: $2,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,284 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,283.64 |
| Education | $237.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,681.43 | 2019-2025 | Stelara, Tremfya, Simponi |
| Abbvie INC. | $2,803.39 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,490.43 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,176.55 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $825.58 | 2019-2024 | |
| Madrigal Pharmaceuticals | $517.73 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $500.84 | 2024-2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $331.16 | 2020-2023 | Stelara |
| Ardelyx, INC. | $326.88 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $290.22 | 2019-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $204.98 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $164.46 | 2019-2023 | Dificid, Zinplava |
| Pfizer INC. | $148.54 | 2023-2025 | |
| Braintree Laboratories, INC. | $140.63 | 2019-2025 | Suflave, Sutab |
| Intercept Pharmaceuticals, INC. | $138.23 | 2020-2024 | Ocaliva |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Capsovision, INC. | $81.45 | 2024-2025 | Capsocam Plus |
| Aimmune Therapeutics, INC. | $64.74 | 2024 | |
| Shionogi INC | $49.49 | 2019 | |
| Endogastric Solutions, INC | $45.26 | 2022 | |
| Lilly USA, LLC | $45.08 | 2024-2025 | Omvoh |
| Shire North American Group INC | $42.18 | 2019 | |
| Organon LLC | $42.02 | 2022-2023 | Renflexis, Hadlima |
| Qol Medical, LLC | $32.75 | 2021-2022 | |
| Olympus America INC. | $32.40 | 2019-2024 | Endoclot Phs |
| Daiichi Sankyo INC. | $23.54 | 2019-2021 | |
| Celltrion USA INC. | $18.82 | 2024 | Zymfentra |
| Medtronic, INC. | $18.69 | 2023 | Nexpowder |
| Boston Scientific Corporation | $15.41 | 2025 | General - Biliary Devices |
| Celgene Corporation | $13.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dacosta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.